Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y 12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial Coronary Heart Disease
暂无分享,去创建一个
E. Antman | S. Murphy | C. McCabe | E. Braunwald | K. Winters | S. Wiviott | R. McKay | C. Lazzam | G. Weerakkody | R. Carney | B. D. Behounek
[1] E. Antman,et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (E , 2005, American heart journal.
[2] Lippincott Williams Wilkins,et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2004 .
[3] E. Antman,et al. Clopidogrel resistance: a new chapter in a fast-moving story. , 2004, Circulation.
[4] H. Hod,et al. Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction , 2004, Circulation.
[5] L. Hillis,et al. Antiplatelet therapy for ischemic heart disease. , 2004, The New England journal of medicine.
[6] Deepak L. Bhatt,et al. Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting. , 2003, The Canadian journal of cardiology.
[7] U. Walter,et al. CORONARY ARTERY DISEASE Original Studies Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation , 2003 .
[8] Kevin P. Bliden,et al. Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.
[9] M. Gawaz,et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement , 2003, Thrombosis and Haemostasis.
[10] P. Gurbel,et al. Durability of platelet inhibition by clopidogrel. , 2003, The American journal of cardiology.
[11] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[12] R. Hongo,et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. , 2002, Journal of the American College of Cardiology.
[13] Deepak L. Bhatt,et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. , 2002, Journal of the American College of Cardiology.
[14] Salim Yusuf,et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.
[15] K A Eagle,et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coro , 2001, Journal of the American College of Cardiology.
[16] R. Storey. The P2Y 12 receptor as a therapeutic target in cardiovascular disease , 2001, Platelets.
[17] M. Bertrand,et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.
[18] H. Koike,et al. The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties , 2000, British journal of pharmacology.
[19] S. Pocock,et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. , 1999, The New England journal of medicine.
[20] C. Macaya,et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). , 1998, Circulation.
[21] E. Fleck,et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. , 1998, Circulation.
[22] M. Hadamitzky,et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.
[23] E. Flatau,et al. Bone marrow aplasia associated with ticlopidine therapy , 1993, American journal of hematology.
[24] K. Mann,et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.
[25] B Meier,et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. , 1991, The New England journal of medicine.
[26] R. de Caterina,et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. , 2004, European heart journal.
[27] S. Israels,et al. Platelets and anti-platelet therapy. , 2003, Journal of pharmacological sciences.